Prospective bone ultrasound patterns during childhood acute lymphoblastic leukemia treatment

被引:14
|
作者
Mussa, Alessandro [1 ]
Bertorello, Nicoletta [2 ]
Porta, Francesco [1 ]
Galletto, Chiara [2 ]
Nicolosi, Mario Guido [3 ]
Manicone, Rosaria [2 ]
Corrias, Andrea [1 ]
Fagioli, Franca [2 ]
机构
[1] Univ Turin, Regina Margherita Children Hosp, Dept Pediat Endocrinol & Diabetol, Div Pediat Endocrinol, I-10126 Turin, Italy
[2] Univ Turin, Dept Pediat Oncohematol, I-10126 Turin, Italy
[3] St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy
关键词
Pediatrics; Childhood leukemia; Bone complications; Quantitative ultrasound; Fractures; PHALANGEAL QUANTITATIVE ULTRASOUND; YOUNG-ADULT SURVIVORS; HUMAN FINGER PHALANGES; MINERAL DENSITY; FRACTURE RISK; CHILDREN; TURNOVER; PROPAGATION; GEOMETRY; GROWTH;
D O I
10.1016/j.bone.2009.12.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Bone impairment is a well-known complication in childhood acute lymphoblastic leukemia (ALL) survivors but less is known about bone dynamics during ALL therapy. We longitudinally assessed by Quantitative Ultrasound (QUS) skeletal modifications during this treatment. Materials and methods: Forty-four newly diagnosed ALL children underwent bone measurement by QUS parameters BTT (Bone Transmission Time) and AD-SoS (Amplitude-Dependent Speed of Sound), mainly reliant on bone density and cortical thickness, respectively. Measurements were performed at diagnosis, and 6, 12, and 24 months thereafter. The occurrence of skeletal complications such as fractures, vertebral collapse, osteonecrosis, and osteopenia was related to measurement outcome. Results: A rapid deterioration of bone properties measured by Bit and AD-SoS was evident in the first semester of therapy (p<0.001). Subsequently, the next measurements were characterized by progressive uncoupling of the two QUS parameters (p<0.001). These were both significantly reduced at the end of therapy (p<0.001). Twelve subjects with in-treatment skeletal complications displayed an almost two-fold decrease of both parameters (p<0.001). Bit decreasing more than 1 Standard Deviation (SD) over 6 months of therapy was able to predict skeletal complication occurrence (p<0.001). Conclusion: This report represents the largest longitudinal cohort systematically submitted to bone condition assessment from the beginning to the end of therapy for childhood ALL. Bone deterioration occurs early and persists throughout therapy, consistent with bone properties uncoupling. This pattern possibly reflects an initial impairment of both mineral density and cortical thickness with a subsequent recovery of this latter. QUS permits an early detection of bone deterioration and related skeletal complications in childhood ALL. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1016 / 1020
页数:5
相关论文
共 50 条
  • [31] Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo
    Pasha, Flaka
    Urbancic, Dunja
    Maxhuni, Rufadie
    Krasniqi, Shaip
    Grajcevci Uka, Violeta
    Mlinaric-Rascan, Irena
    CANCERS, 2024, 16 (11)
  • [32] Bone morbidity in pediatric acute lymphoblastic leukemia
    Ahn, Moon Bae
    Suh, Byung-Kyu
    ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 25 (01) : 1 - 9
  • [33] Long-Term Effects on Bone Mineral Density of Different Therapeutic Schemes for Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma during Childhood
    Benmiloud, Sarra
    Steffens, Melanie
    Beauloye, Veronique
    de Wandeleer, Ann
    Devogelaer, Jean-Pierre
    Brichard, Benedicte
    Vermylen, Christiane
    Maiter, Dominique
    HORMONE RESEARCH IN PAEDIATRICS, 2010, 74 (04): : 241 - 250
  • [34] Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study
    Hori, Hiroki
    Kudoh, Tooru
    Nishimura, Shinichiro
    Oda, Megumi
    Yoshida, Makoto
    Hara, Junichi
    Tawa, Akio
    Usami, Ikuya
    Tanizawa, Akihiko
    Yumura-Yagi, Keiko
    Kato, Koji
    Kobayashi, Ryoji
    Komada, Yoshihiro
    Matsuo, Keitaro
    Horibe, Keizo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 387 - 396
  • [35] Bortezomib for the treatment of acute lymphoblastic leukemia
    Bostrom, Bruce
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (07): : 775 - 780
  • [36] Evaluation of the Effects of Different Transfusion Trigger Levels During the Treatment of Childhood Acute Lymphoblastic Leukemia
    Paananen, Pauliina
    Arola, Mikko O.
    Pelliniemi, Tarja-Terttu
    Salmi, Toivo T.
    Lahteenmaki, Paivi M.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (10) : 745 - 749
  • [37] Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota
    De Pietri, Silvia
    Ingham, Anna C.
    Frandsen, Thomas L.
    Rathe, Mathias
    Krych, Lukasz
    Castro-Mejia, Josue L.
    Nielsen, Dennis S.
    Nersting, Jacob
    Wehner, Peder S.
    Schmiegelow, Kjeld
    Hasle, Henrik
    Pamp, Sunje J.
    Mueller, Klaus
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (07) : 1953 - 1962
  • [38] Biology of Childhood Acute Lymphoblastic Leukemia
    Lo Nigro, Luca
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2013, 35 (04) : 245 - 252
  • [39] Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia
    Settin, A.
    Al Haggar, M.
    Al Dosoky, T.
    Al Baz, R.
    Abdelrazik, N.
    Fouda, M.
    Aref, S.
    Al-Tonbary, Y.
    INDIAN JOURNAL OF PEDIATRICS, 2007, 74 (03) : 255 - 263
  • [40] Seizures during treatment of childhood acute lymphoblastic leukemia: A population-based cohort study
    Anastasopoulou, Stavroula
    Heyman, Mats
    Eriksson, Mats A.
    Niinimaki, Riitta
    Taskinen, Mervi
    Mikkel, Sirje
    Vaitkeviciene, Goda E.
    Johannsdottir, Inga Maria
    Myrberg, Ida Hed
    Jonsson, Olafur Gisli
    Als-Nielsen, Bodil
    Schmiegelow, Kjeld
    Banerjee, Joanna
    Ranta, Susanna
    Harila-Saari, Arja
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2020, 27 : 72 - 77